Indivior Reports SUBLOCADE Clinical Trial Results, Significantly Reducing Opioid Use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 17 2025
0mins
Should l Buy INDV?
Source: PRnewswire
- Rapid Reduction in Use: In a randomized double-blind clinical trial, both the 100mg and 300mg doses of SUBLOCADE® reduced opioid use frequency from over 43 instances per week at screening to fewer than three by week three, demonstrating significant efficacy in treating opioid use disorder.
- Higher Dose Advantage: Participants using fentanyl daily or 14 or more times per week showed significantly higher abstinence rates with the 300mg dose compared to the 100mg, suggesting that high-frequency users may benefit from a higher maintenance dose, highlighting the importance of personalized treatment approaches.
- Good Safety Profile: The trial results indicated that injection-site reactions were more common in the 300mg group but were mild to moderate and did not lead to discontinuation, reinforcing confidence in the drug's safety for clinical use.
- Addressing the Opioid Crisis: The findings provide evidence for clinicians navigating the complexities of opioid use disorder in the fentanyl era, emphasizing the need for treatment approaches that adapt to the realities of today's opioid crisis to enhance patient recovery chances.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.760
Low
36.00
Averages
43.75
High
50.00
Current: 33.760
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Indivior Stock Performance Review: Short-Term Decline vs. Long-Term Gains
- Short-Term Fluctuations: Indivior's recent stock price has declined by 0.20% in one day and 0.81% over the past week, indicating a reassessment by investors of the growth prospects and risks associated with the current share price of $35.44, which may impact short-term investor confidence.
- Long-Term Returns: Despite the recent downturn, Indivior has achieved a 49.03% return over the past 90 days and a total shareholder return of 199.07% over the past year, suggesting strong long-term investment value that continues to attract attention.
- Valuation Analysis: With a P/E ratio of 35.7x, Indivior is slightly below the peer average of 36.1x but significantly above the broader pharmaceuticals industry at 19.7x, indicating a premium attached to its earnings profile that could influence future investment decisions.
- Cash Flow Model: While the P/E ratio suggests Indivior is relatively expensive, the SWS discounted cash flow model estimates a fair value of $108.17, implying that the current stock price is materially undervalued, prompting investors to weigh different valuation signals.
See More
Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million
- Reduction Action: Stonepine Capital reduced its Indivior stake by 250,000 shares in Q3, leading to a valuation drop of approximately $2.75 million, indicating a cautious outlook on the company's future performance.
- Position Change: As of September 30, Stonepine held 100,000 shares of Indivior valued at $2.41 million, with its stake percentage decreasing from 5.06% to 1.96%, reflecting diminished confidence in the stock.
- Performance Metrics: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, showcasing improved operational momentum.
- Future Guidance: Indivior's management raised its full-year 2025 revenue guidance sharply to $1.18 billion to $1.22 billion and plans to save at least $150 million in annual operating expenses starting next year, demonstrating a strategic commitment to cost discipline and sustained growth.
See More
Stonepine Capital Reduces Indivior Stake by $2.75 Million
- Share Reduction: Stonepine Capital Management sold 250,000 shares of Indivior PLC in Q3, reducing its position value by approximately $2.75 million, bringing its holdings down to 100,000 shares worth $2.41 million, reflecting a cautious approach amid market volatility.
- Position Percentage Decline: Following this sale, Indivior now represents only 1.96% of Stonepine's reportable AUM, down significantly from 5.06% in the previous quarter, indicating a strategic reallocation of the investment portfolio.
- Performance Highlights: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, suggesting improving fundamentals for the company.
- Future Outlook: Indivior's management raised its full-year 2025 revenue guidance to between $1.18 billion and $1.22 billion, while also planning to achieve at least $150 million in annual operating expense savings starting next year, demonstrating confidence in sustained growth prospects.
See More
Indivior PLC Added to S&P SmallCap 600 Index, Enhancing Market Presence
- Market Recognition: Indivior PLC's addition to the S&P SmallCap 600 Index today signifies a substantial enhancement in the company's recognition within capital markets, aligning its presence with its refined U.S. business profile.
- Commitment to Growth: CEO Joe Ciaffoni emphasized the company's dedication to expanding the market share of SUBLOCADE®, its leading first-in-class long-acting injectable treatment for moderate to severe opioid use disorder, which is expected to drive future revenue growth.
- Index Background: The S&P SmallCap 600 Index comprises 600 companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable small-cap firms, and Indivior's inclusion is likely to bolster investor confidence.
- Strategic Transformation: By leveraging a simplified operating model, Indivior aims to capitalize on its newly acquired market position to further innovate and develop in the opioid use disorder treatment sector.
See More
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Indivior Stock Performance Review: Short-Term Decline vs. Long-Term Gains
- Short-Term Fluctuations: Indivior's recent stock price has declined by 0.20% in one day and 0.81% over the past week, indicating a reassessment by investors of the growth prospects and risks associated with the current share price of $35.44, which may impact short-term investor confidence.
- Long-Term Returns: Despite the recent downturn, Indivior has achieved a 49.03% return over the past 90 days and a total shareholder return of 199.07% over the past year, suggesting strong long-term investment value that continues to attract attention.
- Valuation Analysis: With a P/E ratio of 35.7x, Indivior is slightly below the peer average of 36.1x but significantly above the broader pharmaceuticals industry at 19.7x, indicating a premium attached to its earnings profile that could influence future investment decisions.
- Cash Flow Model: While the P/E ratio suggests Indivior is relatively expensive, the SWS discounted cash flow model estimates a fair value of $108.17, implying that the current stock price is materially undervalued, prompting investors to weigh different valuation signals.
See More
Stonepine Capital Reduces Indivior Stake by 250,000 Shares, Valuation Drops by $2.75 Million
- Reduction Action: Stonepine Capital reduced its Indivior stake by 250,000 shares in Q3, leading to a valuation drop of approximately $2.75 million, indicating a cautious outlook on the company's future performance.
- Position Change: As of September 30, Stonepine held 100,000 shares of Indivior valued at $2.41 million, with its stake percentage decreasing from 5.06% to 1.96%, reflecting diminished confidence in the stock.
- Performance Metrics: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, showcasing improved operational momentum.
- Future Guidance: Indivior's management raised its full-year 2025 revenue guidance sharply to $1.18 billion to $1.22 billion and plans to save at least $150 million in annual operating expenses starting next year, demonstrating a strategic commitment to cost discipline and sustained growth.
See More
Stonepine Capital Reduces Indivior Stake by $2.75 Million
- Share Reduction: Stonepine Capital Management sold 250,000 shares of Indivior PLC in Q3, reducing its position value by approximately $2.75 million, bringing its holdings down to 100,000 shares worth $2.41 million, reflecting a cautious approach amid market volatility.
- Position Percentage Decline: Following this sale, Indivior now represents only 1.96% of Stonepine's reportable AUM, down significantly from 5.06% in the previous quarter, indicating a strategic reallocation of the investment portfolio.
- Performance Highlights: Indivior reported $314 million in revenue for Q3, with SUBLOCADE sales increasing 15% year-over-year to $219 million, driving a 14% rise in adjusted EBITDA to $120 million, suggesting improving fundamentals for the company.
- Future Outlook: Indivior's management raised its full-year 2025 revenue guidance to between $1.18 billion and $1.22 billion, while also planning to achieve at least $150 million in annual operating expense savings starting next year, demonstrating confidence in sustained growth prospects.
See More
Indivior PLC Added to S&P SmallCap 600 Index, Enhancing Market Presence
- Market Recognition: Indivior PLC's addition to the S&P SmallCap 600 Index today signifies a substantial enhancement in the company's recognition within capital markets, aligning its presence with its refined U.S. business profile.
- Commitment to Growth: CEO Joe Ciaffoni emphasized the company's dedication to expanding the market share of SUBLOCADE®, its leading first-in-class long-acting injectable treatment for moderate to severe opioid use disorder, which is expected to drive future revenue growth.
- Index Background: The S&P SmallCap 600 Index comprises 600 companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable small-cap firms, and Indivior's inclusion is likely to bolster investor confidence.
- Strategic Transformation: By leveraging a simplified operating model, Indivior aims to capitalize on its newly acquired market position to further innovate and develop in the opioid use disorder treatment sector.
See More
